Anesthesia & Analgesia, Vol 86, 579-583, Copyright © 1998 by International Anesthesia Research Society

GENERAL ARTICLES

Treatment of intractable pain with topical large-dose capsaicin: preliminary report

WR Robbins, PS Staats, J Levine, HL Fields, RW Allen, JN Campbell and M Pappagallo
Department of Anesthesia, University of California-San Francisco, 94143, USA.

Complex regional pain syndromes (CRPS) and neuropathic pain are often poorly controlled by conventional pharmacologic interventions. We administered 8-methyl-N-vanillyl-noneamide (capsaicin) at doses of 5%- 10% to individuals with such disorders in this trial. Previous limitations to trials with larger-dose, topical concentrations of capsaicin included intense burning sensations experienced after application. To enable patients to tolerate the high concentrations, we first performed regional anesthesia. All patients reported at least some relief. Of 10 patients, 9 obtained substantial analgesia that lasted 1-18 wk. At Week 1 after therapy, the mean verbal analog scale (VAS) scores decreased from 8.0 to 3.0. At Week 4 after therapy, mean VAS score was 4.5. Analgesia lasted from < 1 wk (1 patient) to more than 50 wk (1 patient). Patients received one to eight treatments. With one exception, patients receiving more than one treatment obtained additional relief with subsequent treatment. Pain responsive to opioids was the only side effect of treatment. Large-dose capsaicin administered with regional anesthesia may effectively minimize refractory CRPS and neuropathic pain. A double-blind, placebo- controlled study in patients with bilateral peripheral neuropathy using epidural anesthesia with and without large-dose topical capsaicin is in progress. IMPLICATIONS: Sensory neuropathies are associated with many diseases. Pain from these disorders can produce greater disability than the primary disease processes themselves. Currently available therapies are limited. However, the intermittent application of large-dose topical capsaicin may provide significant pain relief, decrease chronic analgesic dependence, and decrease aggregate health care expenditures.

This article has been cited by other articles:

				D. M. Simpson, S. Brown, J. Tobias, and For the NGX-4010 C107 Study Group Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy Neurology, June 10, 2008; 70(24): 2305 - 2313. [Abstract] [Full Text] [PDF]

				J. Sawynok Topical and Peripherally Acting Analgesics Pharmacol. Rev., March 1, 2003; 55(1): 1 - 20. [Abstract] [Full Text] [PDF]

				D. G. Witte, S. C. Cassar, J. N. Masters, T. Esbenshade, and A. A. Hancock Use of a Fluorescent Imaging Plate Reader-Based Calcium Assay to Assess Pharmacological Differences between the Human and Rat Vanilloid Receptor J Biomol Screen, October 1, 2002; 7(5): 466 - 475. [Abstract] [PDF]

				E. R. Grant, A. E. Dubin, S.-P. Zhang, R. A. Zivin, and Z. Zhong Simultaneous Intracellular Calcium and Sodium Flux Imaging in Human Vanilloid Receptor 1 (VR1)-Transfected Human Embryonic Kidney Cells: A Method to Resolve Ionic Dependence of VR1-Mediated Cell Death J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 9 - 17. [Abstract] [Full Text] [PDF]

				R. B. Layzer Hot Feet: Erythromelalgia and Related Disorders J Child Neurol, March 1, 2001; 16(3): 199 - 202. [Abstract] [PDF]

				M. PADILLA, G. T. CLARK, and R. L. MERRILL TOPICAL MEDICATIONS FOR OROFACIAL NEUROPATHIC PAIN: A REVIEW J Am Dent Assoc, February 1, 2000; 131(2): 184 - 195. [Abstract] [Full Text] [PDF]

				A. Szallasi and P. M. Blumberg Vanilloid (Capsaicin) Receptors and Mechanisms Pharmacol. Rev., June 1, 1999; 51(2): 159 - 212. [Abstract] [Full Text] [PDF]

				G. Wu, M. Ringkamp, T. V. Hartke, B. B. Murinson, J. N. Campbell, J. W. Griffin, and R. A. Meyer Early Onset of Spontaneous Activity in Uninjured C-Fiber Nociceptors after Injury to Neighboring Nerve Fibers J. Neurosci., April 15, 2001; 21(8): RC140 - RC140. [Abstract] [Full Text] [PDF]